Does mild hepatocellular injury or steatotic liver dysfunction impair LDL particle clearance?

Mild hepatocellular injury and steatotic liver dysfunction significantly disrupt systemic lipid homeostasis by impairing the liver's primary clearance mechanisms for circulating low-density lipoprotein (LDL) particles.

Mechanistic explanations

• SREBP-2 Pathway Activation: Steatotic liver dysfunction and mild hepatocellular injury disrupt intracellular cholesterol homeostatic sensing and trigger endoplasmic reticulum (ER) stress within hepatocytes. This cellular stress state activates sterol regulatory element-binding protein 2 (SREBP-2).
• PCSK9-Mediated Receptor Degradation: Active SREBP-2 directly upregulates the transcription and secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9). Elevated extracellular PCSK9 binds to hepatic cell-surface low-density lipoprotein receptors (LDLR), targeting them for lysosomal degradation and severely reducing their plasma membrane density, even in the presence of compensatory transcriptional signals.

Lipoprotein clearance kinetics

• Impaired Receptor-Mediated Endocytosis: The physical depletion of functional, cell-surface LDLR directly impairs receptor-mediated endocytosis of apolipoprotein B (ApoB)-containing lipoproteins. This represents a critical bottleneck, as cell-surface LDLR abundance is the primary rate-limiting factor for clearing LDL from systemic circulation.
• Prolonged Residence Time: The degradation of LDLR significantly slows the fractional catabolic rate (FCR) of both LDL particles and intermediate-density lipoprotein (IDL) remnants, leading to prolonged systemic circulation times. When combined with increased hepatic secretion of very-low-density lipoprotein (VLDL) characteristic of fatty liver states, this kinetic impairment severely worsens the atherogenic profile.

Bottom line

• Steatotic liver dysfunction impairs lipoprotein handling and worsens LDL particle clearance by activating a pathological SREBP-2/PCSK9 cascade that post-translationally degrades cell-surface LDLR, elevating systemic cardiovascular risk.